JLE

Hépato-Gastro & Oncologie Digestive

MENU

The bright future of hepatology! Second part Volume 24, issue 9, Novembre 2017

Authors
1 CHU Bordeaux, Hôpital Haut-Lévêque, service d’hépato-gastroentérologie et oncologie digestive,
33604 Pessac, France
2 Centre Hospitalier Universitaire, service d’hépato-gastroentérologie, HIFIH, UPRES 3859, SFR 4208, Université LUNAM, Angers, France
3 Hôpital Saint-Antoine, Centre de référence des maladies inflammatoires des voies biliaires,
service d’hépatologie, Bâtiment Jacques Caroli - 8e étage, 184, rue du Faubourg Saint Antoine 75571 Paris Cedex 12, France
4 Hôpital Paul-Brousse, Centre Hépato-Biliaire, Unité Inserm 1193, Université Paris-Sud, Paris Saclay, 94800 Villejuif, France
5 Hôpital Bicêtre, hépatologie et transplantation hépatique pédiatriques, DHU Hepatinov, Université Paris Sud 11, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France et INSERM UMR-S 1174, Université Paris-Sud 11, Orsay, France
6 Hôpital Henri-Mondor, service d’hépatologie, Université Paris-est, INSERM U955, Créteil, France
7 St Mary's Hospital, department of surgery and cancer, liver unit, Imperial College London, UK
8 Hôpital Huriez, service des maladies de l’appareil digestif, 59037 Lille cedex, France
9 Hôpital Jean-Verdier, service d’hépatologie, Bondy ; Université Paris 13, Sorbonne Paris Cité, « Équipe labellisée Ligue Contre le Cancer », F-93206 Saint-Denis ; Inserm, UMR-1162, « Génomique fonctionnelle des tumeurs solides », F-75000, Paris, France
10 CHU Saint-Eloi, service d’hépato-gastroentérologie, 80, rue Augustin Fliche, 34295 Montpellier cedex, France
11 Hôpital Beaujon, service d’hépatologie, DHU Unity, Clichy, France
12 Hôpital de la Pitié-Salpétrière, service d’hépato-gastroentérologie, UPMC, Paris
13 Hospices Civils de Lyon, service d’hépatologie, CRCL-INSERM U1052, Université Lyon 1
* Tirés à part

This second part of the “bright future of hepatology” is devoted to the successes and challenges at the interface between public health, preventive medicine, translational research and international health policy. Indeed, cirrhosis is a disease which prevalence is increasing in France and beyond our borders. Huge challenges remain in the future in terms of prevention which includes alcohol and metabolic syndrome management, screening and early diagnosis. Primary tumors of the liver will always be in the years a public health problem because very related in France to alcohol and the metabolic syndrome. They will represent a significant part of the activity of hepatologists who play and will play a major role in the screening and organization of care. The emergence of new therapeutic tools (targeted therapies, immunotherapy) will transform the treatment of HCC and justify the acquisition of oncology skills by hepatologists who will increase accurate management of both liver and tumor disease that we cannot dissociate. Access to screening and treatment in countries of the South stay problematic and deserve our attention in a globalized world.